Trademark: CT CELLENGENE CELL AND GENE THERAPY 2240839
Word
CT CELLENGENE CELL AND GENE THERAPY
ID
2240839
Trademark Type
Figurative, Fancy
Status
Protected: Registered/protected
Application Date
19 November 2021
Registration Date
19 November 2021
Renewal Date
19 November 2031
Owner(s)
Service
Goods and Services:
Class 5:
Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for medical purposes; stem cells for medical purposes; antidiabetic preparations; anti-diabetic pharmaceuticals; anti-cancer preparations.
Pharmaceutical preparations for treating diabetes; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for medical purposes; stem cells for medical purposes; antidiabetic preparations; anti-diabetic pharmaceuticals; anti-cancer preparations.
Class 42:
Development of cell therapy products; scientific research for medical purposes in the area of cancerous diseases; research services relating to pharmaceuticals; stem cell research services.
Development of cell therapy products; scientific research for medical purposes in the area of cancerous diseases; research services relating to pharmaceuticals; stem cell research services.
Class 44:
Medical services in the field of diabetes; medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow; health care services for treating cancer; medical services relating to the removal, treatment and processing of human cells; medical analysis relating to clinical data.
Medical services in the field of diabetes; medical services relating to the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow; health care services for treating cancer; medical services relating to the removal, treatment and processing of human cells; medical analysis relating to clinical data.